Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper – Haematological malignancies & pediatric oncology

2411 - Polo-like Kinase 1 (PLK1) Inhibitor, Onvansertib, in Combination with Low-Dose Cytarabine or Decitabine in Patients with Relapsed/Refractory Acute Myeloid Leukaemia in Phase 1b


28 Sep 2019


Proffered Paper – Haematological malignancies & pediatric oncology


Amer Zeidan


Annals of Oncology (2019) 30 (suppl_5): v435-v448. 10.1093/annonc/mdz251


A. Zeidan1, P. Becker2, P. Patel3, G. Schiller4, M.L. Tsai5, T. Lin6, E. Wang7, M. Erlander8, J. Cortes9

Author affiliations

  • 1 Hematology, Yale University Hospital, 06511 - New Haven/US
  • 2 Hematology, Seattle Cancer Care Alliance, 98109 - Seattle/US
  • 3 Hematology, UT Southwestern, 75930 - Dallas/US
  • 4 Division Of Hematology-oncology, David Geffen School of Medicine, 90024 - Los Angeles/US
  • 5 Minnesota Oncology, Minneapolis Clinic, Minneapolis/US
  • 6 Hematology, University of Kansas Cancer Center, 66160 - Kansas City/US
  • 7 Hematology, Roswell Park Comprehensive Cancer Center, 14203 - Buffalo/US
  • 8 Research & Development, Trovagene, 92121 - San Diego/US
  • 9 Hematology, MD Anderson Cancer Center, 77030 - Houston/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2411


Polo-like Kinase 1 (PLK1) is a serine/threonine kinase and master regulator of G2/M cell-cycle progression. Inhibition of PLK1 causes mitotic arrest and cell death. Onvansertib is an orally active, highly selective PLK1 inhibitor with demonstrated safety and tolerability (phase 1, solid tumors) and demonstrates activity in preclinical AML models as a single agent and in combination with cytarabine. Previous studies indicate the phosphorylation status of TCTP (pTCTP), a direct substrate for phosphorylation by PLK1, is a biomarker for PLK1 inhibition by onvansertib.


R/R AML patients are treated with onvansertib for 5 days in combination with LDAC or decitabine within 21 to 28-day cycle. Dose escalation is 50% increments with dose limiting toxicity (DLT) evaluated at cycle 1 end. For correlative studies, blood samples were collected on day 1 before (0h) and 3h after treatment and % pTCTP (pTCTP/TCTP) was quantified. Positive target engagement was defined as ≥ 50% decrease in pTCTP/TCTP in 0h vs 3h post-dosing. RNA transcriptome analysis of circulating blasts followed by gene set enrichment analysis (GSEA) was compared between patients with target engagement (TE) vs no target engagement (NTE) pre- and post-dosing (t = 0, 3, 24h).


As of April 1, 2019, 24 pts have completed 1 cycle and in both 1b arms with onvansertib dose escalated from 12, 18, 27, 40 to ongoing 60mg/m2. No DLTs in either arm to-date. For decitabine arm (n = 12), 2 CR’s and 1 CRi observed from 6 evaluable pts in the two highest doses (27 and 40 mg/m2). For LDAC arm, 1 CR observed from 3 evaluable pts in highest dose (40 mg/m2). For pTCTP status, 9 out of the 22 evaluable patients (41%) showed a decrease of ≥ 50% in % pTCTP at 3h post-dose with 5 of 9 having ≥50% decrease in BM blasts; TE was observed in all CR/CRi’s from both arms. GSEA analysis of TE vs NTE indicated an existing upregulation of MYC targets in TE pre-dose which decreased within TE patients 3h/24h post-dosing.


Dose escalation phase of study to-date demonstrates safety, tolerability and anti-leukaemic activity at higher doses that is significantly correlated with pTCTP biomarker status.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

Trovagene, Inc.


Trovagene Oncology.


M. Erlander: Full / Part-time employment: Trovagene. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings